OBJECTIVES: Upon completion of this activity, the participant should be able to – (1) Identify appropriate clinical and/or pathologic staging for improving knowledge to various forms of malignancy by discussion of national treatment guidelines, (2) Define and differentiate the various treatment and management options for pre- and post-surgery cases, (3) Recognize available and appropriate clinical trials and provide enrollment options.

PLANNER/MODERATOR DISCLOSURE:  Prasanthi Ganesa, MD is a speaker for Astra Zeneca Pharmaceutical Company.  Daniel R. Eickenhorst, MD, has no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABS CC: Successful completion of this CME activity enables the learner to earn credit toward the CME requirement of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

For information, please contact William Murphy at [email protected].